The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase III study of MEDI4736 (M), an anti-PD-L1 antibody, in monotherapy or in combination with Tremelimumab (T), versus standard of care (SOC) in patients (pts) with advanced non-small cell lung cancer (NSCLC) who have received at least two prior systemic treatment regimens (ARCTIC).
 
David Planchard
No Relationships to Disclose
 
Mikhail Shtivelband
Honoraria - Bristol-Myers Squibb; Novartis
 
Kelvin Shi
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca; AstraZeneca (I); Clovis Oncology; Clovis Oncology (I); Forest Laboratories; Forest Laboratories (I); Ironwood Pharmaceuticals; Ironwood Pharmaceuticals (I)
 
Ramy Ibrahim
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Marc Ballas
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca; Bristol-Myers Squibb
 
Jean-Charles Soria
Honoraria - AstraZeneca
Consulting or Advisory Role - AstraZeneca